A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (KTE-C19) Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
KITE

Protocol Number
KTE-C19-107 ZUMA7

Phase of Trial
Phase III

To Learn More Call
(201)-510-0950